Asahi Kasei Bioprocess America and GeminiBio team up to advance application of inline buffer formulation

By Rachel Arthur

- Last updated on GMT

Asahi Kasei Bioprocess America and GeminiBio team up to advance application of inline buffer formulation

Related tags Asahi Kasei buffers Us

Asahi Kasei Bioprocess America and GeminiBio have entered into a strategic partnership to advance the application of inline buffer formulation (IBF) in the biopharmaceutical industry.

The combination of Asahi Kasei Bioprocess’ system with GeminiBio’s pre-mixed concentrates into one package can result in a ‘new level of efficiency and cost savings throughout the biopharmaceutical manufacturing process, yielding benefits throughout the entire value chain’, say the companies.

Buffers are used extensively in the development and manufacturing process for all biopharmaceuticals. But the manufacturing of buffers is time consuming and resource intensive, and often a significant bottleneck in the biopharmaceutical manufacturing process, note the two companies.

Asahi Kasei Bioprocess - a subsidiary of Japanese multinational Asahi Kasei – has designed its MOTIV IBF system to debottleneck downstream processing to move product more efficiently through the manufacturing process. However, creating the buffer concentrates that are used with these systems has remained a challenge.

Pairing MOTIV with GeminiBio’s pre-mixed concentrates provides biopharmaceutical manufacturers a total solution, say the companies.

This will result in fewer bottlenecks in manufacturing, streamlining the IBF process.

“Our partnership with GeminiBio solidifies both companies’ commitment to improving the efficiency and efficacy of buffer formulation,” says Chris Rombach, Senior Vice President of Sales and Marketing at Asahi Kasei Bioprocess America.

“The combination of Asahi Kasei Bioprocess America’s long-standing buffer formulation expertise and GeminiBio’s state-of-the-art buffer concentrate manufacturing capabilities will aid bioprocessors to reduce costs, minimize facility footprint and assure on time, every time buffer production.”

The initial scope of the partnership is the North American biopharmaceutical industry.

Moving forward, the companies expect to be able to benefit from the open sharing of data and joint testing to better acclimate the MOTIV system to support a wider variety of pre-mixed buffer concentrates as the variety of the concentrates diversifies.

”We are excited to collaborate with Asahi Kasei Bioprocess to help the biotech industry further address the buffer bottleneck”, said Brian Parker, CEO of California-headquartered GeminiBio.

“GeminiBio is committed to helping our customers simplify upstream and downstream process liquid manufacturing, and supporting inline dilution with ready to use buffer concentrates for the MOTIV IBF system allows us to provide an even higher level of simplification for our customers.”

Follow us